NCT05120271View on ClinicalTrials.gov

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2042

Conditions
Hepatocellular CarcinomaSquamous Cell Carcinoma of the LungMerkel Cell CarcinomaMyxoid/Round Cell Liposarcoma
Interventions
BIOLOGICAL

CAR-GPC3 T Cells

Five dose levels each with LD chemotherapy

Trial Locations (8)

53226

Froedtert and Medical College of Wisconsin, Milwaukee

75246

Baylor Scott and White Research Institute, Dallas

92663

Hoag Hospital Newport Beach, Newport Beach

98109

Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location, Seattle

77030-4008

University of Texas MD Anderson Cancer Center, Houston

G61 1BD

Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre, Glasgow

NW1 2PG

University College London Hospitals NHS Foundation Trust, London

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

All Listed Sponsors
collaborator

SOTIO Biotech a.s.

INDUSTRY

collaborator

SOTIO Biotech AG

INDUSTRY

lead

Sotio Biotech Inc.

INDUSTRY

NCT05120271 - BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | Biotech Hunter | Biotech Hunter